The SUPERNOVA trial was a huge opportunity to test a monoclonal antibody treatment, aimed at offering enhanced protection for immunocompromised individuals against emerging variants of COVID-19.

By the time the trial launched, attitudes toward COVID-19 had evolved significantly. The challenge was to introduce a COVID-19 clinical trial in a post-pandemic world, where misinformation spread and many people had returned to their pre-pandemic routines. To address this, we knew we needed a clear strategy to raise awareness, engage our audience in a way that made them feel seen and understood, and identify eligible patients for the trial.

To gain deeper insight into the mindset of our target population, we spoke directly with immunocompromised individuals. Many expressed that they still felt as though they were “hiding” from COVID-19, which inspired the creation of our ‘Hide or Seek’ campaign.

This initiative empowered patients by offering them the option to seek out new treatments, including clinical trials, in a way that made them feel more in control.

We directed patients to a user-friendly website where they could easily complete a pre-screening questionnaire. Our Faze1 call centre then quickly processed these screenings and referred eligible patients to trial sites. Throughout the campaign and on the website, our messaging was clear, transparent and supportive, offering the information patients needed with a compassionate tone.

As a result, 240 patients were successfully enrolled in the trial and thousands more signed up for our future trials database, eager to learn about upcoming opportunities.